Skip to main content

Historical Bulking Agents

Bulking agents now withdrawn or largely abandoned. They remain on the reconstructive radar because prior-treatment patients still present with sequelae.

The four foundational historical agents now have dedicated pages:

  • Teflon (PTFE / Polytef) — first-ever urologic bulking agent (Politano 1964) and basis of the original STING procedure; abandoned after distant-particle migration.
  • Contigen (GAX-collagen) — first FDA-approved (1993); voluntarily discontinued by the manufacturer in 2011.
  • Autologous Fat — abandoned after the only RCT showed no benefit over saline and a treatment-related death from pulmonary fat embolism.
  • Autologous Chondrocytes — tissue-engineered Atala / Diamond program; never FDA-approved; abandoned after volume loss, relapse, and 37% mound calcification at 9 years.

Why These Remain on the Reconstructive Radar​

  • Calcified mounds from prior subureteral implants (autologous chondrocytes, Deflux) can mimic UVJ stones on imaging.
  • Adult patients with prior periurethral fat or Contigen injection may present years later with recurrent SUI from graft resorption.
  • Prior PTFE/STING patients can present with imaging abnormalities, calcified pelvic lymph nodes, or rare late teflonomas.
  • None of these prior exposures contraindicate subsequent surgical reconstruction (sling, AUS, ureteral reimplantation).

See also: Bulkamid, Macroplastique, Deflux.